REG - Immupharma PLC - Result of General Meeting and TVR

ImmuPharmaAnnouncement

Today 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260407:nRSG4894Za&default-theme=true

RNS Number : 4894Z  Immupharma PLC  07 April 2026

 

7 April 2026

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Result of General Meeting and TVR

 

           Resolutions Approved

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, is pleased to announce that both resolutions proposed at the General
meeting held earlier today were approved by Shareholders.

 

This is further to its Fundraising announcement published on 17 March 2026 at
7:00 a.m. (the "Fundraising RNS") and the WRAP Retail Offer announcement
published on 17 March 2026 at 7:01 a.m. (the "WRAP RNS"),

 

Details of the voting are as set out below:

 

 ORDINARY RESOLUTION                                                              For         % For   Against    % Against  Withheld
 1. That the directors be authorised for the purpose of Section 551 of the        77,375,610  91.46%  7,228,476  8.54%      1,056,465
 Companies Act 2006 (the "Act") to allot shares on the basis as set out in the
 Notice of Meeting
 SPECIAL RESOLUTION                                                               75,221,313  88.91%  9,378,404  11.09%     1,060,834
 2. That, subject to the passing of Resolution 1 the directors be and they are
 hereby empowered pursuant to section 570 of the Act to allot equity securities
 as set out in the Notice of Meeting

 

Allotment of Shares

 

At a Board meeting held following the General Meeting, 100,000,000
Subscription Shares, 12,000,000 Value Payment Shares, 7,812,447 WRAP Retail
Offer Shares and 1,375,000 Fee Shares (together the  "New Ordinary Shares")
have been allotted.

 

Application has been made for the New Ordinary Shares to be admitted to
trading on AIM ("Admission"), and Admission is expected to occur at 8.00 a.m.
on 8 April 2026.

 

Total Voting Rights

 

Upon admission of the New Ordinary Shares, the Company's issued ordinary share
capital will comprise 623,911,379 Ordinary Shares with one voting right each.
The Company does not hold any Ordinary Shares in treasury. This figure may be
used by Shareholders in the Company as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

All New Ordinary Shares have been issued free of all liens, charges and
encumbrances and will, from Admission, rank pari passu in all respects with
the Company's existing Ordinary Shares.

 

Terms used but not defined in this announcement have the same meaning as set
out in the Fundraising RNS and / or WRAP RNS.

 

For further information, please contact:

 

 ImmuPharma PLC (www.immupharma.co.uk)       +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations    + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)     +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)    44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                   +44 (0) 1483 413500

 Nick Emerson

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk) .

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMUPUBWCUPQGUM



            Copyright 2019 Regulatory News Service, all rights reserved